Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw. 2017 Jan;15(1):92-120. doi: 10.6004/jnccn.2017.0008.

Abstract

Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC. This manuscript discusses the recommendations outlined in the NCCN Guidelines for diagnosis, staging, treatment, and follow-up.

Publication types

  • Practice Guideline

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Biopsy
  • Carcinoma, Squamous Cell / diagnosis*
  • Carcinoma, Squamous Cell / epidemiology
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy
  • Female
  • Humans
  • Medical Oncology / standards
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Recurrence, Local / therapy
  • Neoplasm Staging
  • Papillomavirus Infections / diagnosis*
  • Papillomavirus Infections / epidemiology
  • Papillomavirus Infections / pathology
  • Papillomavirus Infections / therapy*
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Survival Rate
  • Vulvar Neoplasms / diagnosis*
  • Vulvar Neoplasms / epidemiology
  • Vulvar Neoplasms / pathology
  • Vulvar Neoplasms / therapy*

Substances

  • Antineoplastic Agents